Latest Funding Strategy News

Theta Gold Mines has locked in a US$90 million senior secured bond and raised US$18.6 million in equity, pushing its TGME Gold Project construction steadily towards first gold in early 2027.

Iondrive Limited has independently confirmed strong rare earth recoveries from U.S. magnet waste and gained Oklahoma government support for its first commercial processing module, advancing its U.S. commercialisation strategy.

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.

N1 Holdings delivered a record quarter for settlement volumes and cash receipts despite a tough interest rate environment, driving a 10% rise in FY26 revenue to $21.67 million and $1.21 million net profit before tax.

Anson Resources has applied to acquire 1,175 acres of lithium-rich brine mineral rights in Utah, aiming to boost its Green River Lithium Project and support a JORC resource upgrade in Q3 2026.

Highfield Resources has obtained a fourth tranche of A$700,000 under its Convertible Note Facility despite a legal event releasing noteholders from future funding obligations. The company continues its Supreme Court appeal and funding discussions to advance the Muga Potash Project.

Investigator Silver has moved the Paris Silver Project decisively from study to execution, bolstered by a strong cash position and key executive hires to drive development and financing.

Norwest Minerals has revised its Bulgera Gold Project resource to 191,000 ounces with 76% in the Indicated category and reported strong metallurgical recoveries supporting heap leach development. The company launched a partly underwritten $1.89 million entitlement offer to fund ongoing studies.

MoneyMe ended FY26 with a loan book exceeding $2 billion and achieved positive Normalised NPAT in the second half, supported by strong originations and improved credit metrics.

Cambium Bio has raised just over A$1 million through a strategic placement at a 17% premium, boosting a key shareholder’s stake as it advances its pivotal Phase 3 trial for dry eye disease.

Control Bionics has closed its Share Purchase Plan, raising $256,500 and pushing total capital raised to $9.75 million, pending shareholder approval for the final tranche.

FBR has locked in a binding agreement for an initial $900,000 convertible note issue, with options to raise up to $3.87 million subject to shareholder approval and other conditions. The funds will support general working capital as the company explores a confidential acquisition opportunity.